NasdaqGS:TERNPharmaceuticals
Terns Pharmaceuticals (TERN) Is Up 6.8% After Leerink Highlights TERN-701’s Early ‘Best-in-Class’ Potential – Has The Bull Case Changed?
In recent days, Leerink Partners initiated coverage on Terns Pharmaceuticals, highlighting early Phase 1 CARDINAL trial data suggesting TERN-701 may offer a best-in-class efficacy and safety profile for chronic myeloid leukemia.
This attention comes shortly after Terns raised US$747.5 million through a public offering and revised its Hansoh licensing deal for oncology rights in mainland China and Taiwan, underscoring the company’s growing oncology ambitions.
Next, we’ll examine how...